Molecular mechanisms of the development and progression of gastric cancer such as the role of E-cadherin, transforming growth factor β or RUNX3 have also been extensively studied by the integrated pathological research, and these molecular technologies may promise to prevent and treat the disease in future.3-5 Advances in diagnosis and treatment have resulted in the improvement in long-term survival for patients at least with early cancer, but the prognosis remains poor for those with advanced cancer. Here, RUNX3 is linked to cancer.